ACR Convergence

An official publication of the ACR and the ARP serving rheumatologists and rheumatolgy professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • ACR Open Rheumatology
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Trump Administration to Appeal Ruling Blocking Price Disclosure for Drug Ads

Carl O'Donnell  |  Issue: April 2008  |  August 21, 2019

(Reuters)—The Trump administration is appealing a court ruling that struck down its plan to compel pharmaceutical companies to disclose wholesale prices of their drugs in televisions advertisements.

The U.S. Department of Health and Human Services (HHS) filed a notice of appeal on Wednesday, as it prepares to challenge the July federal court ruling.

“If the drug companies are embarrassed by their prices or afraid that the prices will scare patients away, they should lower them,” said Caitlin Oakley, a spokeswoman for HHS.

In his ruling, U.S. District Judge Amit Mehta in Washington said that HHS lacked the authority from U.S. Congress to compel drug manufacturers to disclose list prices.

The administration issued the rule in May.

The rule, which applied to drugs with list prices exceeding $35 for a one-month supply, is part of a broader push by President Donald Trump to lower drug prices.

HHS said in July that it and the U.S. Food and Drug Administration will propose a rule that will allow it to authorize states and other groups to pursue pilot projects related to importing drugs from Canada.

Reuters has previously reported that the administration is considering broadening its plans to link the cost of some drugs for the government Medicare program to an international pricing index.

Reporting by Carl O’Donnell Editing by Sonya Hepinstall

Share: 

Filed under:Drug Updates Tagged with:Advertisingdrug costdrug pricestelevision advertisementsTrump administration

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2000-2023 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences